Portugal

 

Portugal’s hospital market: IPO, reform and intrigue

The growth of PMI makes Portugal an exciting market for hospitals. With the IPO of a major hospital group on the cards, reform looking to change the way public-private partnerships are paid, and political intrigue which rivals Game of Thrones, HBI digs into what’s making the market tick.
September 8, 2023

HBI 2023: The outpatient differential

For years there has been a trend towards using outpatient services wherever possible - to improve patient outcomes, to better use an increasingly scarce workforce, and to increase cost efficiency. On the “Outpatient differential” panel at HBI 2023, how this push looks across the world was a key topic for discussion.
July 12, 2023

PP in Valencia defends Alzira model

For-profit hospital group Ribera Salud says that having won the May 2023 elections, the new Partido Popular (PP) administration in Valencia is keen to protect and grow the Alzira model that was being dismantled by the previous leftist government. Meanwhile, Ribera is growing in the Middle East.
June 30, 2023

€1bn+ Luz Saúde IPO could mark return of European health care listings

Luz Saúde, Portugal’s second largest private hospital group by revenue, is set to become a listed company once again after five years of being privately held, in an IPO which could mark the return of European health care listings. The group’s insurer owner Fidelidade plans to retain a strategic majority stake.
May 26, 2023

Orpea restructuring: What will it look to sell?

It has been almost six months since under-fire French nursing home giant Orpea announced plans to get its core business back on track, restructure its debt, and sell around €1.2bn worth of real estate over the next three years. As discussions separating the wheat from the chaff go on behind closed doors, HBI asks three experts where, and what it might sell, and reviews what other French operators like Korian are doing to repair reputation.
May 5, 2023

Mubadala-backed M42 buying Diaverum “for $2bn+”

Swedish multinational dialysis firm Diaverum is being bought by M42, a joint venture between Abu Dhabi sovereign wealth fund Mubadala Investment Co and AI firm G42, for a reported $2bn-$2.5bn. Diaverum’s CEO tells HBI the deal offers further opportunities to develop its digital strategies, and international expansion. 
April 19, 2023
Newer posts
Older posts

Our Services

Company

Resources

Log in
Register
Log in
Register

Our Services

Company

Resources

Find Us